Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV2xO4RJOi53LUG1JI5O MmrpO|IhcA>? MoWxbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NG\Je2MzPTd7MEmwOy=>
U2932  Mkf6R4VtdCCYaXHibYxqfHliQYPzZZk> MXKyMlUuOTVibl2= MkDzO|IhcA>? NY\mUW04cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MknRNlU4QTB7MEe=
OCI-LY7 NVyyW41GS2WubDDWbYFjcWyrdImgRZN{[Xl? MVKyMlUuOTVibl2= NXS4XHpSPzJiaB?= M1L2PIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MlHCNlU4QTB7MEe=
Farage MkS0R4VtdCCYaXHibYxqfHliQYPzZZk> NI[wZXIzNjVvMUWgcm0> MUi3NkBp M1yzXolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NYXOWmtJOjV5OUC5NFc>
LY7/EBV NVX3RoxSS2WubDDWbYFjcWyrdImgRZN{[Xl? NEfKU24zNjVvMUWgcm0> M376UlczKGh? MlPXbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M3LXbFI2PzlyOUC3
U2932/EBV NHXISXdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4X2R|IvPS1zNTDuUS=> MmLmO|IhcA>? MlLwbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NXrYXmI1OjV5OUC5NFc>
HCT116 NXi0e4o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPSSlQ2NTVyMECgcm0> MWOyOEBp NYjL[WRyTE2VTx?= M3POV4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NVHXNmhROjV2OUK1NVU>
ACH-2 NH;YSXlHfW6ldHnvckBCe3OjeR?= M2G2dlEuQSCwTR?= NH;wepMzPCCq MVXpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u NEP3XHIzPTF2OUS2Oy=>
MCF-10A M2rkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7uTWM2OD1yLkG3xtExNjBzIH7N NX\vUmQ1OjR7NUS4OVY>
MCF-7 M3Hzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTWTWM2OD1zLkGwxtExNjJyIH7N MVuyOFk2PDh3Nh?=
SK-BR-3 NWPCPGF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TNNmlEPTB;MT6wNOKyOC5|NTDuUS=> NVTJfIl4OjR7NUS4OVY>
MDA-MB-231 NEnnOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwNklCtVAvOTRibl2= MV:yOFk2PDh3Nh?=
PC3 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr5TWM2OD1zLk[1xtExNjN3IH7N NHnxTFgzPDl3NEi1Oi=>
HCT116 M4S3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj6WZc4UUN3ME2xMlAxyrFyLkCwJI5O NFi3cGwzPDl3NEi1Oi=>
HCT116-p21-/- M4DwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfxOXFKSzVyPUGuNlbDuTBwM{egcm0> M2XsNVI1QTV2OEW2
S1 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\vXGlEPTB;Nz62O:KyOC5{OTDuUS=> NEHXeZczPDl3NEi1Oi=>
SW620 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHkTWM2OD1yLkmzxtExNjJ7IH7N M4DW[|I1QTV2OEW2
LOX-IMVI NWfWbYJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPV[WozUUN3ME2wMlg4yrFyLkCzJI5O M4DwW|I1QTV2OEW2
UACC-62 NVfYWY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DlTGlEPTB;MD61OuKyOC5zNjDuUS=> Mof2NlQ6PTR6NU[=
MDA-MB-435 NXLMW2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LvTGlEPTB;MD65NOKyOC5yNjDuUS=> NGO1b3QzPDl3NEi1Oi=>
SF-295 M3TvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe3e5ZKSzVyPUCuPFjDuTBwMUWgcm0> Mm\3NlQ6PTR6NU[=
A549 NXzTboY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnpO4lGUUN3ME2xMlI3yrFyLkK0JI5O M4PETVI1QTV2OEW2
H460 NHzwU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfhTWM2OD1{LkW4xtExNjhyIH7N NF3p[YozPDl3NEi1Oi=>
EKVX MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwM{RCtVAvOzRibl2= MWCyOFk2PDh3Nh?=
H146 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnURppIUUN3ME2wMlIzyrFyLkC3JI5O NXPFZXZPOjR7NUS4OVY>
H526 M2XGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjCO3lKSzVyPUCuNVXDuTBwMEOgcm0> M4HGdVI1QTV2OEW2
HuT-78 NUn3VFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG1TmVKSzVyPUGuO|PDuTBwNESgcm0> MUKyOFk2PDh3Nh?=
HA NYDWUXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\CeYMxNjZ{NT2xNI5O M{fpVFQ5KGh? M1e3Solv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj MUGyOFc4OTVzMB?=
MS-275 NWfpSmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuxNE43OjVvMUDuUS=> MnPyOFghcA>? NFPvWm9qdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? MVeyOFc4OTVzMB?=
CD4 T MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r1VlQ5KGh? MnPKSWM2OD12LkZCtVEvOCCwTR?= M2\OT|I1PzJ{NEW0
CD4 T NEf0bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVznTJNSPDhiaB?= NV;rfWFVS0N3ME2xNFfDuTF{NjDuUS=> M3\oUlI1PzJ{NEW0
CD4+ T M{HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLFR|UxRTNibl2= MXiyOFQ6PTFyNR?=
A549 NWHMbpUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:xNQKBmzFyMNMgcm0> MUiyOE8{Pi92ODDo MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MWGyOFQ5PTd7OR?=
JJN3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTMXVUzPC92ODDo NYfjU3lRTUN3MEyx5qCKdk19IES45qCKcA>? NHL5SJIzPDB|MEG1NC=>
OPM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LZR|I1NzR6IHi= MX\FR|Uxez1z4pEJcm08KDR64pEJbC=> NGTOfXQzPDB|MEG1NC=>
RPMI-8226 M{n1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETNSnczPC92ODDo NVHt[4czTUN3MIO9NU456oDLbl27JFQ56oDLaB?= NV:5ZW5vOjRyM{CxOVA>
U266 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKyOE81QCCq NVHweIJbTUN3MIO9NVDjiImwTUugOFjjiImq MYOyOFA{ODF3MB?=
CA46 NYDNNFdySXCxcITvd4l{KEG|c3H5 NGjSeZY3KGh? M{TBeolv\HWlZYOgZox2dnRiYYDvdJRwe2m| NXnnUJd1OjN7Nk[xOlQ>
DG75 NFHQb4lCeG:ydH;zbZMhSXO|YYm= NF\uZYo3KGh? NWnwPIhucW6mdXPld{BvdyCjcH;weI9{cXN? M4rOWlI{QTZ4MU[0
Ramos NH7rdXhCeG:ydH;zbZMhSXO|YYm= NXTQW4RoPiCq MlvNbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz MknGNlM6PjZzNkS=
ST486 NIjIXFlCeG:ydH;zbZMhSXO|YYm= MWK2JIg> MV;pcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= MYWyN|k3PjF4NB?=
HuT78 NVnDdm1FSXCxcITvd4l{KEG|c3H5 M{ixN|EwOTBxMUCwJI5O MVK0PEBp MVvpcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P MXqyN|U{Ojd|Mh?=
DpVp35 NGXMdmlCeG:ydH;zbZMhSXO|YYm= Mn\jNU8yOC9zMECgcm0> NIq5T4s1QCCq NYHvWVExcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MnjONlM2OzJ5M{K=
DpVp50 NVm0TYFXSXCxcITvd4l{KEG|c3H5 MUCxM|ExNzFyMDDuUS=> NIqyNWg1QCCq MmDrbY5lfWOnczDicJVvfCCjcH;weI9{cXN? NXfx[nd2OjN3M{K3N|I>
DpP75  NYDPNXlGSXCxcITvd4l{KEG|c3H5 NVHP[2UxOS9zMD:xNFAhdk1? NIDEZmg1QCCq NEfMNlBqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NHW5e|UzOzV|MkezNi=>
SKOV-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHznOGIy6oDVMkDuUS=> M2PqXFczKGh? M3jDR2ROW09? MkjEdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NGjicXQzOzBzMEO0PC=>
Brca1 WT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUToWWw{OeLCk{Kwcm0> M32xb|czKGh? MYHEUXNQ M3i3W5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NXO0TItLOjNyMUCzOFg>
Brca1 Null NV\QXlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK1NgKBmzJybl2= M4PuSFczKGh? NEj6bWhFVVOR MkXkdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NH\GcpAzOzBzMEO0PC=>
OVCAR-8  MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSx5qCUOjCwTR?= NVjC[3dxPzJiaB?= MVnEUXNQ MoSydoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> M{PSXlI{ODFyM{S4
NCI/ADR-RES MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W2bVHjiJN{MH7N NGfyd4E4OiCq NYDLXpBtTE2VTx?= MorudoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NXu2bYg2OjNyMUCzOFg>
HCT116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW1JI5ONTVyIN88US=> NVfoSFB4OjRiaB?= MWnEUXNQ MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M1HyOlIzQTJ2OUW4
RKO NW\WT5NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjfJFNPSCwTT21NEDPxE1? NFrtV3AzPCCq MWPEUXNQ Ml\lbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NHnsR|kzOjl{NEm1PC=>
CO115 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzIdow2KG6PLUWwJO69VQ>? NHe2UJYzPCCq NESy[HdFVVOR MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MoXPNlI6OjR7NUi=
HFS Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm1JI5O MkH6NlQwPDhxN{KgbC=> M4fDe4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MnfrNlIyODZ{OEK=
LNCaP M3vE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLpOUBvVQ>? MUSyOE81QC95MjDo NIjqcFJqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 NIPpcHYzOjFyNkK4Ni=>
A549 NWLIXFA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS1JI5O MWOyOE81QC95MjDo NF63ZlBqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 NF3BfoMzOjFyNkK4Ni=>
697  NYLnN|kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvvXo9KSzVy4pEJQgKBkTJwNdMgcm0> MUCyNVU{QDJzNh?=
697-R MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq1TWM2OOLCiU5ihKk5NjcEoH7NxsA> MUGyNVU{QDJzNh?=
HUT78 NEL5bWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\KNmlEPTB;MTDuUS=> M1jiNVIyOTl6NUS1
THJ-16T M{Xp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjMNUBvVQ>? NGTuTJIzPCCq MoXUbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M33QOFIxQDFyNU[4
HCT116 M1\mSmZ2dmO2aX;uJGF{e2G7 NHfFWXkzOCCwTR?= NX21XXNwQCCq MlzscY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w MmG5NlA4Ozl2NUS=
B104  MX\GeY5kfGmxbjDBd5NigQ>? NGHQWXUzKG6P Mmq0NlQwPDhxN{KgbC=> NYToTJkycW6lcnXhd4V{KHSqZTDzeZJn[WOnIHX4dJJme3Orb36gc4YhS0R{MNMg M4K3[FIxPjh4NUC1
HL-60  NXTwdoVHS3m2b4TvfIlkcXS7IFHzd4F6 M37OSVEuPTByIH7N NX3NOlE3OjRiaB?= MUHpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NXXUUIo1OjB4MkSxOlM>
HP100 M37sSWN6fG:2b4jpZ4l1gSCDc4PhfS=> NXv3SG1KOS13MECgcm0> NX3IPWN7OjRiaB?= NHPaclFqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NEHjUJozODZ{NEG2Ny=>
HL-60  NYW3SopJTnWwY4Tpc44hSXO|YYm= MU[xNEBvVQ>? MVS0M|YwOTZiaB?= MWXpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? MWCyNFYzPDF4Mx?=
HP100 M1XDbmZ2dmO2aX;uJGF{e2G7 MnvDNVAhdk1? MXK0M|YwOTZiaB?= NXzl[VB5cW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo M37qS|IxPjJ2MU[z
HL-60  M1[zeWZ2dmO2aX;uJGF{e2G7 M3K5d|ExNTVyMDDuUS=> M2ToR|QhcA>? M2nxOIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NUe3bWZVOjB4MkSxOlM>
HP100 NXvLd29VTnWwY4Tpc44hSXO|YYm= MUSxNE02ODBibl2= Ml\DOEBp NYPMWJZ3\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg MmTuNlA3OjRzNkO=
11z NF7zRXJMcW6jc3WgRZN{[Xl? NVzEUnVEOy1zMECgcm0> Mk\mdoVlfWOnczDISGFEKGWweontZZRq[yCjY4Tpeol1gSBqSVO1NOKhRSB4LkWgxtEhOC54IH7tc4wwVCl? NHP1UGMzODZyNUG0OC=>
SKOV-3 NFLpO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVu0M|gwOTZibl2= NIixWW01QCCq NUT5[3ZDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MUGyNFQxPDV4NB?=
OVCAR-3 M3TFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjYOE85NzF4IH7N MW[0PEBp M3\xdolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MVqyNFQxPDV4NB?=
HBL-2 M2LW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSyMVExKG6P NX;MdIpiOjRiaB?= MVvJR|UxRTRwMzDuUS=> NGLGbZozODB4OEC4NC=>
Jeko-1 M2HSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmyMVUxKG6P M4\kdlI1KGh? MlHTTWM2OD1zMTDuUS=> MYKyNFA3QDB6MB?=
Granta-519 NXzQZnp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS1MVQxKG6P NYW1PZI6OjRiaB?= NFPjR3JKSzVyPUW4MlUhdk1? NWLRd2lxOjByNkiwPFA>
L1236 MV7DfZRwfG:6aXPpeJkhSXO|YYm= M2n4dlEhdk1vMUCwJO69VQ>? NEKwXYc1QCCq NWjDb5F4TUN3ME2wMlA4KM7:TR?= M2fpfVE6OjN|NEew
L428 NEH5PGlEgXSxdH;4bYNqfHliQYPzZZk> MnLqNUBvVS1zMECg{txO MkDTOFghcA>? MXXFR|UxRTBwNEOg{txO NGLSZ2gyQTJ|M{S3NC=>
KM-H2 NGnoe5VEgXSxdH;4bYNqfHliQYPzZZk> Mn;WNUBvVS1zMECg{txO MknWOFghcA>? M1\oZ2VEPTB;MD61PEDPxE1? MlnKNVkzOzN2N{C=
L540Cy MkDHR5l1d3SxeHnjbZR6KEG|c3H5 MluxNUBvVS1zMECg{txO NVX3OmI2PDhiaB?= Mo[1SWM2OD1yLkG2JO69VQ>? MV[xPVI{OzR5MB?=
G401 MULGeY5kfGmxbjDBd5NigQ>? NIPzW5kyOCCwTR?= MV[yOE81QC95MjDo M2[w[mROW09? MlnEbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MoWxNVkzOjF3OE[=
STM91-01 MX;GeY5kfGmxbjDBd5NigQ>? NFfHOoQyOCCwTR?= MV[yOE81QC95MjDo NX;nOG12TE2VTx?= NXjo[|dYcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MVGxPVIzOTV6Nh?=
SJSC  M1;teGZ2dmO2aX;uJGF{e2G7 M2PlS|ExKG6P NELsbYEzPC92OD:3NkBp NF7DfHVFVVOR NGnjbIxqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NX;h[Yl7OTl{MkG1PFY>
BT16  MkPqSpVv[3Srb36gRZN{[Xl? M33qflExKG6P M{nQdlI1NzR6L{eyJIg> MXXEUXNQ MWfpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MWSxPVIzOTV6Nh?=
NCI-H1299 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jE[mlEPTB;ND62xtExNjJibnevcYw> MkHTNVkyPzl6OUC=
NCI-2882 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ZSmlEPTB;MT62xtExNjB2IH7nM41t M3fTXFE6OTd7OEmw
HCC95 NH;YV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LEeWlEPTB;Mj61xtExNjB3IH7nM41t MXuxPVE4QTh7MB?=
NCI-H23 NWXxbmdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn2XFdKSzVyPUKuPeKyOC5{IH7nM41t MnftNVkyPzl6OUC=
NCI-H157 NEWwUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXXTWM2OD1zLkdCtVAvODJibnevcYw> MUGxPVE4QTh7MB?=
NCI-H460 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnOTWM2OD1{LkJCtVAvODdibnevcYw> MlHnNVkyPzl6OUC=
NCI-H1975 M3Hl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwM9MxNE4xPCCwZz;tcC=> MXWxPVE4QTh7MB?=
NCI-H820 NXLOT2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[wXXdKSzVyPUKuOOKyOC5zIH7nM41t NYDlT3d6OTlzN{m4PVA>
NCI-H1650 NEexNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwOdMxNE4{KG6pL33s NHXiPVUyQTF5OUi5NC=>
DTC1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDvTWM2OD1yLkWxJI5O MlPNNVg2PjZ{NE[=
KAO NVGyeZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\lbllKSzVyPUCuPVEhdk1? M4DJ[VE5PTZ4MkS2
SU-CCS-1 M1\Tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO4TWM2OD1yLki5JI5O M1vaSFE5PTZ4MkS2
SYO-1 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNkegcm0> NWXofFZUOTh3Nk[yOFY>
FUJI Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qXWlEPTB;MT6zNUBvVQ>? M3flVFE5PTZ4MkS2
SKNMC NWXsZ4NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwMUegcm0> MYixPFU3PjJ2Nh?=
402-91 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLMTWM2OD1zLkK2JI5O NGDQTGoyQDV4NkK0Oi=>
1765-92 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwN{egcm0> NGHyOGQyQDV4NkK0Oi=>
JN-DSRCT-1 M33EfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTufpFKSzVyPUGuNlUhdk1? MkjCNVg2PjZ{NE[=
NMS-2PC NVrTVpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2zOXRKSzVyPUCuPFEhdk1? NV7Fflg3OTh3Nk[yOFY>
HL60 NHjJT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXFTWM2OD1zLki2JI5O MlPJNVg2PjZ{NE[=
A549 M3rtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13UcWlEPTB;Mz6yOEBvVQ>? Mkn2NVg2PjZ{NE[=
SW480 NVzaXY9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwNkmgcm0> NVHwUHI{OTh3Nk[yOFY>
MCF7 NGjre|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPYdnNKSzVyPUOuOVUhdk1? M1LnZlE5PTZ4MkS2
PC-3 NELPXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj2Ro1KSzVyPUKuOVEhdk1? M3jIT|E5PTZ4MkS2
MMRU MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\PbYUxUUN3ME2yMlU4KG6P NXXVPFRtOTh3Nk[yOFY>
Hs68 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRT5zMDDuUS=> NFrZb3oyQDV4NkK0Oi=>
hMSC-001F M4LybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17FVWlEPTB;PkGwJI5O MYmxPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID